Decision on IPR: Nov 08, 2018
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
US Patent
|
Respondent
|
Status
|
|
IPR2018-00186
|
12/01/2017
|
06/14/2018
|
Pfizer, Inc.
|
9,296,821
|
Biogen Inc.
|
Terminated
|
On US’821 patent, Celltrion previously filed IPR (IPR2017-01095) in which Board on Oct 04, 2018 issued final written decision & found claims 1-6 unpatentable.
US 9,296,821 (Biogen Inc; Exp: Jun 11, 2019) – Non OB
1. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient a therapeutically effective amount of rituximab during a chemotherapeutic regimen, wherein the chemotherapeutic regimen consists of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the method comprises administering 375 mg/m2 of rituximab, and wherein the method provides a beneficial synergistic effect in the patient.
2. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient 375 mg/m2of C2B8 during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy).
3. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient 375 mg/m2of a chimeric anti-CD20 antibody during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the chimeric anti-CD20 antibody is produced from nucleic acid encoding a light chain variable region comprising the amino acid sequence in SEQ ID NO: 1 and a heavy chain variable region comprising the amino acid sequence in SEQ ID NO: 2, and comprises human gamma 1 heavy-chain and kappa light-chain constant region sequences.
4. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient a therapeutically effective amount of rituximab during a chemotherapeutic regimen, wherein the chemotherapeutic regimen consists of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the method comprises administering 375 mg/m.sup.2 of rituximab once every 3 weeks for 8 doses, and wherein the method provides a beneficial synergistic effect in the patient.
5. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient 375 mg/m2of C2B8 once every 3 weeks for 8 doses during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy).
6. A method for treating low grade or follicular non-Hodgkin’s lymphoma (NHL) comprising administering to a patient 375 mg/m2of a chimeric anti-CD20 antibody once every 3 weeks for 8 doses during a chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and prednisone (CVP therapy), wherein the chimeric anti-CD20 antibody is produced from nucleic acid encoding a light chain variable region comprising the amino acid sequence in SEQ ID NO: 1 and a heavy chain variable region comprising the amino acid sequence in SEQ ID NO: 2, and comprises human gamma 1 heavy-chain and kappa light-chain constant region sequences.
Leave a Reply